ClinicalTrials.gg

Program

ITU512

A development code.

In Novartis's pipeline, HbF inducing agent. Its studies are mostly in Anemia, Sickle Cell, led by Novartis.

Furthest: phase 2, since Jul 16, 20241 company-led study, 1 open or runningNext primary completion: May 1, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 2since Jul 16, 2024Jul 16, 2024May 1, 2028phase 2 · NCT06546670
  • Named in Novartis’s own pipeline as ITU512, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2024First study: phase 2 study in Anemia, Sickle CellFirst studyNCT06546670 · 161 planned · United States, Brazil, Turkey (Türkiye)

Ahead

  1. May 1, 2028Primary completion: phase 2 study in Anemia, Sickle CellNCT06546670

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“HbF inducing agent”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06546670Anemia, Sickle Cell · United States, Brazil, Turkey (Türkiye)2RecruitingMay 1, 2028161

How it is read

Names in the registry

  • “ITU512”, 1 entry

Codes read as this program: ITU512.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.